Business
Steriwave enters ICU and related Issue of Shares
Steriwave enters ICU and related Issue of Shares.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n19 March 2025\nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\", or the \"Company\")\n \nFirst patients recruited into Steriwave ICU pilot study and related Issue of Shares\n \nOndine Biomedical Inc. (LON: OBI), a global leader in light-activated antimicrobial technologies, is pleased to announce that patient recruitment has commenced in an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. Treating patients in intensive care units (ICUs) with Ondine's Steriwave® nasal photodisinfection technology would significantly expand the market opportunity for Steriwave.\n \nInfection prevention is a top priority in ICUs, where higher infection rates, critically ill patients, and bed capacity shortages create significant challenges. Unlike traditional antibiotics, Steriwave does not generate antimicrobial resistance. Already in use across Canada and in several UK NHS trusts before major surgery, this technology helps reduce the incidence of surgical site infections (SSIs) by decolonizing the nose-a major reservoir of infection-causing pathogens.\n \nThe first patients were enrolled at RCH on 18 March 2025 for the four-month pilot involving approximately 400 ICU patients. This important study aims to evaluate the feasibility of conducting a larger safety and efficacy study of Steriwave in reducing hospital-acquired infections (HAIs) among critically ill patients in the ICU. HAIs, often caused by multidrug-resistant organisms, represent a growing challenge to healthcare systems worldwide.\n \nRCH, a level 1 trauma centre and one of the busiest in Canada, is the first to explore the use of Ondine's Steriwave nasal decolonization technology in ICUs. Conducted by ICU physician, Dr. Reynolds and his research team, this pilot study will evaluate how Steriwave can integrate into ICU infection control and workflow protocols and will make a preliminary assessment of its potential impact on infection rates, length of stay and patient mortality.\n \nThis Investigator-Initiated Study (IIS), first announced 25 September 2024, was designed by Dr. Stephen Reynolds in collaboration with the RCH Foundation's Advancing Innovation in Medicine (AIM) division. Depending on the results, the pilot could pave the way for a larger multicentre trial involving...